Brussels, Brussels Hoofdstedelijk Gewest, Belgium In 2017 was created Newton Biocapital, which is appeared as VC. The main office of represented VC is situated in the Brussels. The fund was located in Europe if to be more exact in Belgium.
The current fund was established by Alain Parthoens. The overall number of key employees were 7.
This Newton Biocapital works on 12 percentage points less the average amount of lead investments comparing to the other organizations. The important activity for fund was in 2018. Considering the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 investment rounds annually. The top amount of exits for fund were in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - Belgium. Among the various public portfolio startups of the fund, we may underline DIM3, Synergia Medical, ChromaCure The fund has no specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Project Management, Manufacturing.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Newton Biocapital, startups are often financed by VI Partners AG, Neomed Management, Entrepreneurs Fund. The meaningful sponsors for the fund in investment in the same round are S.R.I.W., SFPI-FPIM, CapDecisif. In the next rounds fund is usually obtained by Go Capital, CapDecisif, Anaxago.
Related Funds
Funds with similar focus
| Fund Name | Location |
| BBVA | Panamá, Panama, Panama City |
| BLC Bank | Beirut, Beyrouth, Lebanon |
| Clear Ventures | California, Palo Alto, United States |
| Cornel Capital Partners | Chicago, Illinois, United States |
| DKR Capital | Connecticut, Stamford, United States |
| Evergrande Health Industry Group | China, Guangdong, Guangzhou |
| Grand Sud Ouest Capital | Aquitaine, Bordeaux, France |
| Halton | Kentucky, Scottsville, United States |
| Highway 12 Ventures | Boise, Idaho, United States |
| Integrale Advisors | California, Sunnyvale, United States |
| Ningo Meishan Baoshui Gangqu Yunwanxingtong Investment Management | China, Ningbo, Zhejiang |
| Pomona Impact | - |
| Sazze Partners | California, San Jose, United States |
| Shidu Zichan | Beijing, China, Haidian |
| SLD Entertainment | Japan, Minato |
| Startupbootcamp InsurTech London | England, London, United Kingdom |
| Umusun Lab | Japan, Okinawa, Okinawa Prefecture |
| Universal Materials Incubator | Japan, Tokyo |
| Uphold | California, San Francisco, United States |
| Yuxin Jiuding (Xiamen) Touzi Guanli Zhongxin | - |
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AbolerIS Pharma | $32M | 19 Sep 2023 | Nantes, Pays de la Loire, France | ||
Santero Therapeutics | $9M | 08 Jun 2023 | Charleroi, Hainaut, Belgium | ||
AdipoPharma | 23 Jan 2023 | Illkirch-graffenstaden, Alsace, France | |||
DeuterOncology | $6M | 19 Jan 2023 | Belgium, Antwerp, Belgium | ||
NeuVasQ | $23M | 24 Jun 2021 | Gosselies, Hainaut, Belgium | ||
DeuterOncology | 24 Feb 2021 | Belgium, Antwerp, Belgium | |||
AbolerIS Pharma | $2M | 04 Nov 2020 | Nantes, Pays de la Loire, France | ||
Acticor Biotech | $8M | 06 Nov 2019 | France, Ile-de-France | ||
EditForce | $7M | 01 Mar 2019 | Fukuoka, Fukuoka Prefecture, Japan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AbolerIS Pharma | $32M | 19 Sep 2023 | Nantes, Pays de la Loire, France | ||
Santero Therapeutics | $9M | 08 Jun 2023 | Charleroi, Hainaut, Belgium | ||
AdipoPharma | 23 Jan 2023 | Illkirch-graffenstaden, Alsace, France | |||
DeuterOncology | $6M | 19 Jan 2023 | Belgium, Antwerp, Belgium | ||
NeuVasQ | $23M | 24 Jun 2021 | Gosselies, Hainaut, Belgium | ||
DeuterOncology | 24 Feb 2021 | Belgium, Antwerp, Belgium | |||
AbolerIS Pharma | $2M | 04 Nov 2020 | Nantes, Pays de la Loire, France | ||
Acticor Biotech | $8M | 06 Nov 2019 | France, Ile-de-France | ||
EditForce | $7M | 01 Mar 2019 | Fukuoka, Fukuoka Prefecture, Japan |
